Cytokines as the Basis of Therapy
To understand the mechanism of action of this drug group, it is necessary to recall the basic principles of the immune system. Interleukin drugs belong to the broad class of cytokines. Under natural conditions, endogenous cytokines are produced by the body itself and act as universal regulators. They transmit signals between cells, coordinating both the immune response against foreign agents and hematopoiesis (blood formation). The creation of recombinant analogs of these substances has allowed pharmacologists to directly intervene in immunological reactions. By administering such drugs exogenously, we can purposefully enhance the proliferation of desired cells, activate their protective functions, or restore impaired hematopoiesis.
Aldesleukin: Recombinant Analog of IL-2
One of the key representatives of this group is aldesleukin. Pharmacologically, this drug is an exact recombinant analog of endogenous interleukin-2. Its pharmacodynamics is based on the ability to specifically bind to IL-2 receptors located on the membranes of target cells.
Upon receptor binding, a complex cascade of reactions is triggered, leading to the following effects:
- Powerful stimulation of T-lymphocyte differentiation and proliferation.
- Activation of growth and development of other cell populations whose survival directly depends on the presence of interleukin-2.
- Significant enhancement of the cytotoxicity of lymphocytes and specialized killer cells (NK cells). These cells acquire a pronounced ability to recognize and destroy tumor cells.
- The drug acts as an inducer, prompting the immune system to produce several other vital cytokines. Specifically, it induces the synthesis of interferon-gamma (IFN-γ), tumor necrosis factor (TNF), and interleukin-1.
Due to this pronounced antineoplastic effect, the primary clinical indication for prescribing aldesleukin is renal cell carcinoma.
Betaleukin: Stimulator of Hematopoiesis and Immunity
The second important drug in this group is betaleukin, which is human recombinant interleukin-1β. Unlike aldesleukin, the pharmacodynamics of betaleukin has a distinct dual focus, affecting both hematopoiesis and cellular immunity.
- Hemostimulatory action. Betaleukin actively intervenes in hematopoiesis by activating the production of specific colony-stimulating factors in the body. As a result of this cascade, the proliferation (multiplication) and differentiation (maturation) of cells belonging to various hematopoietic lineages are significantly enhanced.
- Immunostimulatory action. The drug directly affects white blood cells, substantially increasing the functional activity of neutrophils and lymphocytes.
The main indication for betaleukin is leukopenia (a decrease in the blood leukocyte count). Most commonly, this condition is caused by aggressive medical interventions, such as courses of chemotherapy using cytotoxic agents or exposure to ionizing radiation.
When prescribing betaleukin, the physician must consider potential side effects. Therapy may be accompanied by hyperthermia (elevated body temperature), severe chills, and headache.